SCHEMBL6802382

SCHEMBL6802382

O=c1c2cc(F)c(N3CCCC3)cc2n(C2CC2)c(=O)n1O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 1/20 0.42
TOP2A P11388 1/20 0.42
CYP2C9 P11712 1/20 0.42
TOP2B Q02880 1/20 0.42
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 1/20 0.37
IP6K1 Q92551 1/20 0.37
THRB P10828 4/20 0.36
POLB P06746 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797651 0.85 PRKD3 (0.42) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6800209 0.84 PIM1 (0.51) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL13713252 0.84 PIM1 (0.51) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6800877 0.83 GSK3B (0.37) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL13713249 0.83 GSK3B (0.37) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6800873 0.83 GSK3B (0.37) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6795074 0.82 TOP1 (0.54) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6795945 0.82 MAPT (0.45) LMNAMAPTMEN1GAAKMT2A
SCHEMBL6802393 0.81 TOP1 (0.39) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6806737 0.80 TOP2A (0.38) KDM4EALDH1A1HPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP claimed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A LMNA 3642/4885KDM4E 2528/4885ALDH1A1 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.